Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 2 Trial of Doxorubicin Plus Pemetrexed Followed by Docetaxel, Versus Doxorubicin Plus Cyclophosphamide Followed by Docetaxel, as Neoadjuvant Treatment for Early Breast Cancer. [STUDIO RANDOMIZZATO DI FASE II DI CONFRONTO TRA DOXORUBICINA + PEMETREXED SEGUITO DA DOCETAXEL VERSUS DOXORUBICINA + CICLOFOSFAMIDE SEGUITO DA DOCETAXEL, COME TRATTAMENTO NEOADIUVANTE DEL TUMORE DELLA MAMMELLA IN STADIO INIZIALE]

Next Previous
X
Search
Trial Profile

A Randomized Phase 2 Trial of Doxorubicin Plus Pemetrexed Followed by Docetaxel, Versus Doxorubicin Plus Cyclophosphamide Followed by Docetaxel, as Neoadjuvant Treatment for Early Breast Cancer. [STUDIO RANDOMIZZATO DI FASE II DI CONFRONTO TRA DOXORUBICINA + PEMETREXED SEGUITO DA DOCETAXEL VERSUS DOXORUBICINA + CICLOFOSFAMIDE SEGUITO DA DOCETAXEL, COME TRATTAMENTO NEOADIUVANTE DEL TUMORE DELLA MAMMELLA IN STADIO INIZIALE]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Doxorubicin (Primary) ; Pemetrexed (Primary)
  • Indications Early breast cancer
  • Focus Pharmacogenomic; Therapeutic Use

    • Most Recent Events

    • 05 Jun 2012 Results at 3 years presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jun 2010 Analysis investigating the correlation between the CD24 ala/val polymorphism and the pathological complete response at the 46th Annual Meeting of the American Society of Clinical Oncology.
    • 31 May 2009 Results were presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top